Percutaneous Left Atrial Appendage Closure in Patients With Cardioembolic Breakthrough Stroke: An International Observational Study.
Saved in:
| Title: | Percutaneous Left Atrial Appendage Closure in Patients With Cardioembolic Breakthrough Stroke: An International Observational Study. |
|---|---|
| Authors: | Galea, Roberto (AUTHOR), Casu, Gavino (AUTHOR), Bini, Tommaso (AUTHOR), Laconi, Angelo (AUTHOR), Merella, Pier Luigi (AUTHOR), Chalkou, Konstantina (AUTHOR), Preda, Alberto (AUTHOR), Cerciello, Marco (AUTHOR), D'Angelo, Giuseppe (AUTHOR), Bella, Paolo della (AUTHOR), Mazzone, Patrizio (AUTHOR), Auer, Elias (AUTHOR), Gasys, Antanas (AUTHOR), Seiffge, David Julian (AUTHOR), Fischer, Urs (AUTHOR), Räber, Lorenz (AUTHOR) |
| Source: | European Journal of Neurology. Sep2025, Vol. 32 Issue 9, p1-8. 8p. |
| Subjects: | Left atrial appendage closure, Atrial fibrillation, Anticoagulants, Secondary prevention, Surgical complications, Treatment effectiveness, Ischemic stroke |
| Abstract: | Background: Patients with non‐valvular atrial fibrillation (AF) who experience an ischemic stroke despite oral anticoagulation (OAC) are at particularly high risk of recurrence, with a reported annualized ischemic stroke rate of 5.3%–8.9%. The optimal strategy for secondary prevention in these patients remains unknown. Methods: We reviewed all percutaneous left atrial appendage closures (LAAC) attempted in AF patients experiencing an ischemic stroke under OAC and who were prospectively collected in four European centers. All index strokes were categorized by an experienced neurologist to exclude patients with non‐cardioembolic etiology or insufficient OAC. The primary endpoint was a recurrent ischemic stroke at 2 years after the procedure. Secondary endpoints included procedure‐related complications and 2‐year death. Results: Of 2234 patients submitted to LAAC procedure, 95 had a cardioembolic breakthrough stroke. LAAC procedures were performed at a mean of 4 months after the breakthrough stroke. The main antithrombotic therapy at discharge (83%) and at the latest follow‐up (79%) consisted of OAC. At the median follow‐up of 713 days, the primary endpoint occurred in 4 patients (4%). Procedure‐related complications were rare (1%) whereas death occurred in 5% of patients. Conclusion: LAAC procedures were safe and feasible in patients with cardioembolic breakthrough stroke. Recurrent stroke rates were lower than those reported in previous studies with OAC continuation after breakthrough stroke, suggesting a potential additive protection by LAAC on top of OAC. Results from ongoing randomized trials are required to validate our findings. [ABSTRACT FROM AUTHOR] |
| Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Patients with non‐valvular atrial fibrillation (AF) who experience an ischemic stroke despite oral anticoagulation (OAC) are at particularly high risk of recurrence, with a reported annualized ischemic stroke rate of 5.3%–8.9%. The optimal strategy for secondary prevention in these patients remains unknown. Methods: We reviewed all percutaneous left atrial appendage closures (LAAC) attempted in AF patients experiencing an ischemic stroke under OAC and who were prospectively collected in four European centers. All index strokes were categorized by an experienced neurologist to exclude patients with non‐cardioembolic etiology or insufficient OAC. The primary endpoint was a recurrent ischemic stroke at 2 years after the procedure. Secondary endpoints included procedure‐related complications and 2‐year death. Results: Of 2234 patients submitted to LAAC procedure, 95 had a cardioembolic breakthrough stroke. LAAC procedures were performed at a mean of 4 months after the breakthrough stroke. The main antithrombotic therapy at discharge (83%) and at the latest follow‐up (79%) consisted of OAC. At the median follow‐up of 713 days, the primary endpoint occurred in 4 patients (4%). Procedure‐related complications were rare (1%) whereas death occurred in 5% of patients. Conclusion: LAAC procedures were safe and feasible in patients with cardioembolic breakthrough stroke. Recurrent stroke rates were lower than those reported in previous studies with OAC continuation after breakthrough stroke, suggesting a potential additive protection by LAAC on top of OAC. Results from ongoing randomized trials are required to validate our findings. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13515101 |
| DOI: | 10.1111/ene.70365 |
